Crescent Biopharma, Inc.

CBIO

CBIOCrescent Biopharma, Inc. US flag

NASDAQ Capital Market

16.64

USD

+1.59

- -

458.80MMarket Cap

Income Statement (USD)

API ChatGPT

	2024 Y	2025 Y
As of date	12/31/2024	12/31/2025

Sales/Revenue/Turnover	- -	11
+ Sales & Services Revenue	- -	11
- Cost of Revenue	- -	- -
+ Cost of Goods & Services	- -	- -
Gross Profit	- -	- -
+ Other Operating Income	- -	-11
- Operating Expenses	- -	163
+ Selling, General & Admin	- -	25
+ Research & Development	- -	138
+ Other Operating Expense	- -	- -
Operating Income (Loss)	- -	-153
- Non-Operating (Income) Loss	- -	-1
+ Interest Expense, Net	- -	-1
+ Interest Expense	- -	2
- Interest Income	- -	3
+ Other Non-Op (Income) Loss	- -	- -
Pretax Income	- -	-152
- Income Tax Expense (Benefit)	- -	2
- (Income) Loss from Affiliates	- -	- -
Income (Loss) from Cont Ops	- -	-154
- Net Extraordinary Losses (Gains)	- -	- -
+ Discontinued Operations	- -	- -
+ Extraord. & Accounting Changes	- -	- -
Income (Loss) Incl. MI	- -	-154
- Minority Interest	- -	- -
Net Income, GAAP	- -	-154
- Preferred Dividends	- -	- -
- Other Adjustments	- -	- -
Net Income Avail to Common, GAAP	- -	-154
EBIT	- -	-153
EBITDA	- -	-153
EBITDA Margin (%)	- -	-1,406.75
EBITA	- -	-153
Gross Margin (%)	- -	100
Operating Margin (%)	- -	-1,407.52
Profit Margin (%)	- -	-1,419.61
Sales per Employee	- -	- -
Dividend per Share	- -	- -
Depreciation Expense	- -	- -
Basic Weighted Avg Shares	- -	10
Basic EPS, GAAP	- -	-14.78
Basic EPS from Cont Ops	- -	-14.78
Diluted Weighted Avg Shares	- -	10
Diluted EPS, GAAP	- -	-14.78
Diluted EPS from Cont Ops	- -	-14.78

Balance Sheet (USD)

API ChatGPT

	2024 Y	2025 Y
As of date	12/31/2024	12/31/2025

Total Current Assets	35	237
+ Cash, Cash Equivalents & STI	35	213
+ Cash & Cash Equivalents	35	213
+ ST Investments	- -	- -
+ Accounts & Notes Receiv	- -	18
+ Accounts Receivable, Net	- -	18
+ Notes Receivable, Net	- -	- -
+ Loans Receivable, Net	- -	- -
+ Other Receivable, Net	- -	- -
+ Inventories	- -	- -
+ Raw Materials	- -	- -
+ Work In Process	- -	- -
+ Finished Goods	- -	- -
+ Inventory Adjustments	- -	- -
+ Other Inventory	- -	- -
+ Other ST Assets	- -	5
+ Misc ST Assets	- -	- -
+ Prepaid Expenses	- -	- -
+ ST Derivative & Hedging Assets	- -	- -
+ ST Assets Held-for-Sale	- -	- -
+ ST Deferred Tax Assets	- -	- -
Total Noncurrent Assets	1	4
+ Property, Plant & Equip, Net	- -	2
+ Property, Plant & Equip	- -	2
- Accumulated Depreciation	- -	- -
+ LT Investments & Receivables	- -	- -
+ LT Investments	- -	- -
+ LT Receivables	- -	- -
+ Other LT Assets	1	1
+ Total Intangible Assets	- -	- -
+ Goodwill	- -	- -
+ Other Intangible Assets	- -	- -
+ LT Deferred Tax Assets	- -	- -
+ LT Derivative & Hedging Assets	- -	- -
+ Misc LT Assets	1	1
Total Assets	36	240
+ Payables & Accruals	10	21
+ Accounts Payable	- -	10
+ Accrued Taxes	- -	8
+ Interest & Dividends Payable	- -	- -
+ Other Payables & Accruals	9	3
+ ST Debt	- -	- -
+ ST Borrowings	- -	- -
+ ST Finance Leases	- -	- -
+ Other ST Liabilities	- -	14
+ Deferred Revenue	- -	4
+ Derivatives & Hedging	- -	- -
+ Deferred Tax Liabilities	- -	- -
+ Misc ST Liabilities	- -	10
Total Current Liabilities	10	36
+ LT Debt	37	1
+ LT Borrowings	37	- -
+ LT Finance Leases	- -	1
+ Other LT Liabilities	4	- -
+ Accrued Liabilities	- -	- -
+ Pension Liabilities	- -	- -
+ Deferred Revenue	- -	- -
+ Deferred Tax Liabilities	- -	- -
+ Derivatives & Hedging	- -	- -
+ Misc LT Liabilities	4	- -
Total Noncurrent Liabilities	41	1
Total Liabilities	51	37
+ Preferred Equity and Hybrid Capital	- -	4
+ Share Capital & APIC	2	371
+ Common Stock	- -	- -
+ Additional Paid in Capital	2	371
- Treasury Stock	- -	- -
+ Retained Earnings	-18	-172
+ Other Equity	- -	- -
Equity Before Minority Interest	-15	203
+ Minority/Non Controlling Interest	- -	- -
Total Equity	-15	203
Total Liabilities & Equity	36	240
Shares Outstanding	20	30
Number of Employees	- -	- -
Capital Leases - Total	- -	2
Net Debt	3	-213
Net Debt to Equity	-17.55	-105.01
Tangible Common Equity Ratio	-43.46	82.82
Current Ratio	3.62	6.56
Cash Conversion Cycle	- -	- -

Cash Flow Statement (USD)

API ChatGPT

	2024 Y	2025 Y
As of date	12/31/2024	12/31/2025

+ Net Income	- -	-154
+ Depreciation & Amortization	- -	- -
+ Non-Cash Items	- -	96
+ Stock-Based Compensation	- -	13
+ Deferred Income Taxes	- -	- -
+ Asset Impairment Charge	- -	- -
+ Other Non-Cash Adj	- -	82
+ Chg in Non-Cash Work Cap	- -	-13
+ (Inc) Dec in Accts Receiv	- -	-18
+ (Inc) Dec in Inventories	- -	- -
+ (Inc) Dec in Prepaid Assets	- -	-5
+ Inc (Dec) in Accts Payable	- -	- -
+ Inc (Dec) in Other	- -	9
+ Net Cash From Disc Ops	- -	- -
Cash from Operating Activities	- -	-72
+ Change in Fixed & Intang	- -	- -
+ Disp in Fixed & Intang	- -	- -
+ Disp of Fixed Prod Assets	- -	- -
+ Disp of Intangible Assets	- -	- -
+ Acq of Fixed & Intang	- -	-73
+ Acq of Fixed Prod Assets	- -	-1
+ Acq of Intangible Assets	- -	-72
+ Cash (Repurchase) of Equity	- -	322
+ Increase in Capital Stock	- -	322
+ Decrease in Capital Stock	- -	- -
+ Net Change in LT Investment	- -	- -
+ Dec in LT Investment	- -	- -
+ Inc in LT Investment	- -	- -
+ Net Cash From Acq & Div	- -	- -
+ Cash from Divestitures	- -	- -
+ Cash for Acq of Subs	- -	- -
+ Cash for JVs	- -	- -
+ Other Investing Activities	- -	- -
+ Net Cash From Disc Ops	- -	- -
Cash from Investing Activities	- -	-73
+ Dividends Paid	- -	- -
+ Net Cash From Debt	- -	- -
+ Cash From Debt	- -	- -
+ Repayments of Debt	- -	- -
+ Other Financing Activities	- -	1
+ Net Cash From Disc Ops	- -	- -
Cash from Financing Activities	- -	323
Effect of Foreign Exchange Rates	- -	- -
Net Changes in Cash	- -	179
EBITDA	- -	-153
EBITDA Margin (%)	- -	-1,406.75
Free Cash Flow	- -	-144
Net Cash Paid for Acquisitions	- -	- -
Free Cash Flow to Firm	- -	- -
Free Cash Flow to Equity	- -	-68
Free Cash Flow per Basic Share	- -	-13.87
Price/Free Cash Flow	- -	89.05
Cash Flow to Net Income	- -	0.46
Capital Expenditures	- -	-73